Suscribirse

Bronchial epithelial cell transcriptome shows endotype heterogeneity of asthma in patients with NSAID-exacerbated respiratory disease - 05/04/23

Doi : 10.1016/j.jaci.2022.10.029 
Bogdan Jakiela, MD, PhD a, , Jerzy Soja, MD, PhD a, Krzysztof Sladek, MD, PhD a, Marek Przybyszowski, MD, PhD a, Hanna Plutecka, PhD a, Anna Gielicz, MSc a, Sabina Licholai, MD a, Alar Aab, PhD b, Ana Rebane, PhD b, Grazyna Bochenek, MD, PhD a,
a Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland 
b Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia 

Corresponding author: Grazyna Bochenek, MD, PhD, or Bogdan Jakiela, MD, PhD, Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Jakubowskiego 2, 30-688 Krakow, Poland.Department of Internal MedicineFaculty of MedicineJagiellonian University Medical CollegeJakubowskiego 2Krakow30-688Poland

Abstract

Background

Nonsteroidal anti-inflammatory drugs–exacerbated respiratory disease (N-ERD) is currently classified as a type-2 (T2) immune-mediated disease characterized by asthma, chronic rhinosinusitis, and hypersensitivity to cyclooxygenase-1 inhibitors.

Objectives

The aim of this study was to characterize immunological endotypes of N-ERD based on the gene expression profile in the bronchial epithelium.

Methods

mRNA transcriptome (mRNA-sequencing) was analyzed in bronchial brushings from patients with N-ERD (n = 22), those with nonsteroidal anti-inflammatory drug–tolerant asthma (NTA, n = 21), and control subjects (n = 11). Additionally, lipid and protein mediators were measured in bronchoalveolar lavage fluid (BALF).

Results

Initial analysis of the entire asthma group revealed 2 distinct gene expression signatures: “T2-high” with increased expression of T2-related genes (eg, CLCA1, CST1), and “proinflammatory” characterized by the expression of innate immunity (eg, FOSB, EGR3) and IL-17A response genes. These endotypes showed similar prevalence in N-ERD and NTA (eg, T2-high: 33% and 32%, respectively). T2-high asthma was characterized by increased expression of mast cell and eosinophil markers, goblet cell hyperplasia, and elevated LTE4 and PGD2 in BALF. Patients with a proinflammatory endotype showed mainly neutrophilic inflammation and increased innate immunity mediators in BALF. Furthermore, the proinflammatory signature was associated with a more severe course of asthma and marked airway obstruction. These signatures could be recreated in vitro by exposure of bronchial epithelial cells to IL-13 (T2-high) and IL-17A (proinflammatory).

Conclusions

T2-high signature was found only in one-third of patients with N-ERD, which was similar to what was found in patients with NTA. The proinflammatory endotype, which also occurred in N-ERD, suggests a novel mechanism of severe disease developing on a non-T2 background.

El texto completo de este artículo está disponible en PDF.

Key words : Asthma, NSAID–exacerbated respiratory disease, asthma endotypes, bronchial epithelium, gene expression

Abbreviations used : BALF, cysLTs, DEG, HBECs, N-ERD, NSAIDs, NTA, PNEC, qPCR, T2


Esquema


 Supported by the Polish National Science Center (grants UMO-2014/15/B/NZ5/01539 [to G.B.] and UMO-2014/13/B/NZ3/02393 [to B.J.]). A.R. was supported by a personal research grant (PRG1259) from the Estonian Research Council.
 Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.


© 2022  American Academy of Allergy, Asthma & Immunology. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 151 - N° 4

P. 953-965 - avril 2023 Regresar al número
Artículo precedente Artículo precedente
  • The gut microbiome is a significant risk factor for future chronic lung disease
  • Yang Liu, Shu Mei Teo, Guillaume Méric, Howard H.F. Tang, Qiyun Zhu, Jon G. Sanders, Yoshiki Vázquez-Baeza, Karin Verspoor, Ville A. Vartiainen, Pekka Jousilahti, Leo Lahti, Teemu Niiranen, Aki S. Havulinna, Rob Knight, Veikko Salomaa, Michael Inouye
| Artículo siguiente Artículo siguiente
  • Elarekibep (PRS-060/AZD1402), a new class of inhaled Anticalin medicine targeting IL-4Ra for type 2 endotype asthma
  • Gabriele Matschiner, Mary F. Fitzgerald, Ulrich Moebius, Andreas M. Hohlbaum, Hendrik Gille, Kristian Jensen, Klaus Kirchfeld, Barbara Rattenstetter, Alice Laforge, Rachida S. Bel Aiba, Joe Ciccotosto, Hong Nyugen, Martyn L. Foster, John N. Snouwaert, MyTrang Nguyen, Beverly H. Koller, Louis Matis, Gary P. Anderson, Shane A. Olwill

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.